NCT06008119 2025-09-18Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerShanghai Kechow Pharma, Inc.Phase 3 Recruiting165 enrolled